Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
RCUS
#1597
Arcus Biosciences, Inc.
20.3
8
+4.57%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+4.57%
Monthly Change
-12.53%
6 month change
+92.26%
Year Change
+96.53%
Previous Close
19.4
9
Open
20.1
5
Bid
Ask
Low
20.0
7
High
20.4
4
Volume
601
Markets
US Stock Market
Healthcare
RCUS
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
70.88 M
71.06 M
73.01 M
90.86 M
105.84 M
125.35 M
—
Valuation ratios
Enterprise value
1.67 B
2.73 B
1.27 B
1.66 B
1.43 B
2.77 B
5.25 B
Price to earnings ratio
11.58
57
-5.44
-4.74
-4.74
-7.24
-15.54
Price to sales ratio
18.35
7.82
12.99
12.45
5.2
10.36
24.5
Price to cash flow ratio
12.79
11.69
3.32
4.76
7.89
5.31
13.1
Price to book ratio
2.83
3.56
2.21
3.15
2.77
4.06
5.43
Enterprise value to EBITDA ratio
—
55.14
—
-4.63
-4.02
-6.93
-13.2
Profitability ratios
Return on assets %
0.16
0.03
0.2
0.28
0.25
0.31
0.33
Return on equity %
0.24
0.06
0.41
0.66
0.58
0.56
0.69
Return on invested capital %
178.83
25.71
150.36
320.79
367.92
517.25
—
Gross margin %
100
100
100
100
100
100
400
Operating margin %
160.27
14.17
250
290.6
127.91
156.28
1 332.32
EBITDA margin %
—
12.92
—
-306.84
-137.6
-161.54
-1 369.11
Net margin %
158.49
13.8
238.39
262.39
109.69
142.91
1 240.44
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
6.05
7.6
5.53
4.52
4.5
4.36
17.88
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.16
0.32
0.08
0.1
0.23
0.22
0.22
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
0.04
0.09
0.32
Long term debt to total equity ratio
—
—
—
—
0.1
0.16
0.65
Per share metrics
Operating cash flow per share
2.03
3.46
6.08
4.14
1.89
4.49
4.62
EBIT per share
—
0.73
-3.89
-4.59
-3.66
-3.59
-3.71
EBITDA per share
—
0.67
—
-4.85
-3.94
-3.72
-3.83
Total debt per share
—
—
—
—
—
—
—
Cash per share
3.17
6.75
14.01
10.26
10.85
9.13
35.62
Net current asset value per share
13.43
17.06
14.82
11.23
11.28
9.38
36.78
Tangible book value per share
9.17
11.38
9.13
6.24
5.38
5.88
20.52
Working capital per share
11.21
14.81
12.14
8.74
8.77
7.23
28.5
Book value per share
9.17
11.38
9.13
6.24
5.38
5.88
20.52
News
Arcus Biosciences, Inc. 2025 Q4 - Results - Earnings Call Presentation (NYSE:RCUS) 2026-02-27
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Arcus 2025 presentation: casdatifan data strengthens, I&I pipeline emerges
Arcus Biosciences earnings beat by $0.21, revenue fell short of estimates
Arcus Biosciences in spotlight: Kidney drug trial results at stake
AMD, IBM among market cap stock movers on Tuesday
Arcus reports casdatifan trial data in kidney cancer patients